Date: 2016-06-21
Type of information: Opening of new premises
Compound:
Company: Novadip Biosciences (Belgium)
Therapeutic area: Regenerative Medicine
Type agreement: opening of new premises
Action mechanism:
Disease:
Details: * On June 21, 2016, Novadip Biosciences announced the official opening of its new site in Mont-Saint-Guibert, Belgium. The new facilities include work space for the growing, 16-person team, plus two R&D/QC labs and state-of-the-art GMP cleanrooms for producing clinical batches. The new siteis already fitted with state-of-the-art grade A/B cleanrooms, suitable for GMP production of NVD-001 and NVD-002 clinical batches to support Novadip’s upcoming clinical trials. Starting in December 2015, the company began refurbishing the site, including setting up two R&D/QC labs for the development and characterisation of new products such as NVD-002, dedicated to wound healing. Novadip pioneers the growth of 3-dimensional tissues derived from adipose stem cells to regenerate bone and soft tissues. Its first product, NVD-001, is a ready-to-use and biological 3D osteogenic structure that can be modelled to fill large and small bone defects. The technology has also been used to develop the second family product in the portfolio, NVD-002, a biological bandage for skin tissue applications, designed to avoid formation of painful scars. Both NVD-001 and NVD-002 are obtained from adipose-derived mesenchymal stem cells (AMSCs) cells isolated from a minute quantity of the patient’s own fatty tissue.
Financial terms:
Latest news:
